An overview of the current diagnosis and clinical approaches to treating MOGAD is provided, with emerging biomarkers and novel therapeutic targets currently under investigation, offering promising directions for personalized management.
Abstract
Abstract Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as a distinct clinical entity within the spectrum of central nervous system inflammatory demyelinating disorders. Recent advances have refined its nosological classification, distinguishing it from both multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. The identification of myelin oligodendrocyte glycoprotein-immunoglobulin G through highly specific cell-based assays has been pivotal in recognizing a broader clinical phenotype, including recurrent optic neuritis, longitudinally extensive transverse myelitis, and cerebral cortical encephalitis. Ongoing research highlights differences in immunopathogenesis, relapse risk, and long-term outcomes compared to other demyelinating conditions. Moreover, recent studies support the efficacy of early and sustained immunotherapy, with corticosteroids, intravenous immunoglobulin, and rituximab showing benefits in relapse prevention. Emerging biomarkers and novel therapeutic targets are currently under investigation, offering promising directions for personalized management. This section provides an overview of the current diagnosis and clinical approaches to treating MOGAD.
Current evidence for acute treatment (high-dose corticosteroids, therapeutic plasma exchange, and intravenous immunoglobulin), the corticosteroid taper, and maintenance immunotherapy are synthesized, with attention to when treatment should be started and when it may reasonably be stopped.
João Vitor Mahler, Marina Vilardo, G. Silva et al.· Frontiers in Neurology· 0 citations
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as a distinct inflammatory demyelinating disorder of the central nervous system. Although relatively rare, growing recognition of this entity has highlighted important differences from multiple sclerosis and neuromyelitis optica spectru...
Kavya Rajanna, G. Sharma· International Journal of Con...· 0 citations
Importance
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion di...
Eoin P. Flanagan, Brenda L. Banwell, Laura Cacciaguerra et al.· JAMA Neurology· 0 citations
In the 2023 International Panel’s diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), one of six core clinical demyelinating events (core events) is required: optic neuritis (ON), myelitis, acute disseminated encephalomyelitis (ADEM), cerebral monofocal or polyfocal defici...
Y. Matsumoto, Naoki Yamamoto, K. Kaneko et al.· Brain Communications· 0 citations
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder distinct from multiple sclerosis (MS) and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD). Seizures are an important but incompletely characterized manifestation. Their reported...
Chun Li, Liang-Liang Hao, Xue-Yan Liu et al.· Frontiers in Immunology· 0 citations
Pediatric neuroinflammatory disorders are a heterogeneous group of autoimmune conditions that have evolved rapidly over the past decade and are encountered in both community and specialized pediatric practice. This group can share overlapping features and includes pediatric-onset multiple sclerosis (POMS), acute dissem...
J. Aw-Zoretic· Pediatric Radiology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.